The estimated Net Worth of Paul A Brooke is at least $14 millió dollars as of 21 February 2020. Paul Brooke owns over 20,000 units of Incyte stock worth over $13,988,598 and over the last 21 years Paul sold INCY stock worth over $0.
Paul has made over 11 trades of the Incyte stock since 2004, according to the Form 4 filled with the SEC. Most recently Paul exercised 20,000 units of INCY stock worth $266,800 on 21 February 2020.
The largest trade Paul's ever made was buying 100,000 units of Incyte stock on 9 September 2004 worth over $774,000. On average, Paul trades about 5,254 units every 96 days since 2004. As of 21 February 2020 Paul still owns at least 221,584 units of Incyte stock.
You can see the complete history of Paul Brooke stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... és Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: